Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMM01 + tislelizumab
- Development stage
- Unknown
- Lead developer
- ImmuneOnco
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMM01 + tislelizumab is an investigational combination immunotherapy being evaluated for the treatment of advanced solid tumors and classic Hodgkin lymphoma. IMM01 (timdarpacept) is a recombinant SIRPα-Fc fusion protein that targets the CD47-SIRPα pathway. It is designed with a dual mechanism of action: blocking the 'don't eat me' signal by disrupting the CD47/SIRPα interaction and delivering an 'eat me' signal through its IgG1 Fc domain, which engages activating Fcγ receptors on macrophages. Notably, IMM01 is engineered to avoid binding to human red blood cells, which minimizes the risk of treatment-induced anemia. Tislelizumab is a humanized IgG4 monoclonal antibody directed against the programmed cell death protein 1 (PD-1) receptor, acting as a checkpoint inhibitor to restore T-cell mediated anti-tumor responses. Together, the combination aims to synergistically activate both innate and adaptive immune responses against cancer cells.
- Brand names
- Tevimbra
- Other names
- timdarpacept + tislelizumab
02
Targets
CD47 (Cluster of Differentiation 47)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)PDCD1 (Programmed cell death protein 1 receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on IMM01 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMM01 + tislelizumab.